Trial Profile
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Dec 2017
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Nintedanib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 09 Dec 2008 New trial record.